Tumour burden and efficacy of immune-checkpoint inhibitors
The DOI matches its Crossref record; 163 of the 166 references it cites were found in a registry or an index.
Abstract
Accumulating evidence suggests that a high tumour burden has a negative effect on anticancer immunity. The concept of tumour burden, simply defined as the total amount of cancer in the body, in contrast to molecular tumour burden, is often poorly understood by the wider medical community; nonetheless, a possible role exists in defining the optimal treatment strategy for many patients. Historically, tumour burden has been assessed using imaging. In particular, CT scans have been used to evaluate both the number and size of metastases as well as the number of organs involved. These methods are now often complemented by metabolic tumour burden, measured using the more recently developed 2-deoxy-2-[ 18 F]-fluoro-D-glucose (FDG)-PET/CT. Serum-based biomarkers, such as lactate dehydrogenase, can also reflect tumour burden and are often also correlated with a poor response to immune-checkpoint inhibitors. Other circulating markers (such as circulating free tumour DNA and/or circulating tumour cells) are also attracting research interest as surrogate markers of tumour burden. In this Review, we summarize evidence supporting the utility of tumour burden as a biomarker to guide the use of immune-checkpoint inhibitors. We also describe data and provide perspective on the various tools used for tumour burden assessment, with a particular emphasis on future therapeutic strategies that might address the issue of inferior outcomes among patients with cancer with a high tumour burden.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
The Warburg Effect: How Does it Benefit Cancer Cells?
Liberti, M. V., & Locasale, J. W. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.12.001 · Cited by 5,150
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Nivolumab plus ipilimumab in advanced non-small-cell lung cancer
Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910231 · Cited by 2,823
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552
Self-citationInhibitory effect of tumor cell-derived lactic acid on human T cells
Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., Gottfried, E., Schwarz, S., Rothe, G., Hoves, S., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035972 · Cited by 1,946
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
The TRACERx consortium, Abbosh, C., The PEACE consortium, Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R., Le Quesne, J., Moore, D. A., et al. (2017) · Nature · doi:10.1038/nature22364 · Cited by 1,874
Cellular senescence and the senescent secretory phenotype: therapeutic opportunities
Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J., & Kirkland, J. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64098 · Cited by 1,774
Metabolic support of tumour-infiltrating regulatory T cells by lactic acid
Watson, M. J., Vignali, P. D. A., Mullett, S. J., Overacre-Delgoffe, A. E., Peralta, R. M., Grebinoski, S., Menk, A. V., Rittenhouse, N. L., DePeaux, K., Whetstone, R. D., et al. (2021) · Nature · doi:10.1038/s41586-020-03045-2 · Cited by 1,259
Brenchley, J. M., Karandikar, N. J., Betts, M. R., Ambrozak, D. R., Hill, B. J., Crotty, L. E., Casazza, J. P., Kuruppu, J., Migueles, S. A., Connors, M., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2103 · Cited by 1,073
The hypoxic tumour microenvironment
Petrova, V., Annicchiarico-Petruzzelli, M., Melino, G., & Amelio, I. (2018) · Oncogenesis · doi:10.1038/s41389-017-0011-9 · Cited by 1,019
Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2276 · Cited by 969
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
Méjean, A., Ravaud, A., Thezenas, S., Colas, S., Beauval, J.-B., Bensalah, K., Geoffrois, L., Thiery-Vuillemin, A., Cormier, L., Lang, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803675 · Cited by 946
Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches
de la Cruz-López, K. G., Castro-Muñoz, L. J., Reyes-Hernández, D. O., García-Carrancá, A., & Manzo-Merino, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01143 · Cited by 940
Mezquita, L., Auclin, E., Ferrara, R., Charrier, M., Remon, J., Planchard, D., Ponce, S., Ares, L. P., Leroy, L., Audigier-Valette, C., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4771 · Cited by 913
Self-citationScharping, N. E., Rivadeneira, D. B., Menk, A. V., Vignali, P. D. A., Ford, B. R., Rittenhouse, N. L., Peralta, R., Wang, Y., Wang, Y., DePeaux, K., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00834-9 · Cited by 897
Krebs, M. G., Sloane, R., Priest, L., Lancashire, L., Hou, J.-M., Greystoke, A., Ward, T. H., Ferraldeschi, R., Hughes, A., Clack, G., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.7045 · Cited by 868
We need to talk about the Warburg effect
DeBerardinis, R. J., & Chandel, N. S. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0172-2 · Cited by 850
Ferrara, R., Mezquita, L., Texier, M., Lahmar, J., Audigier-Valette, C., Tessonnier, L., Mazieres, J., Zalcman, G., Brosseau, S., Le Moulec, S., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3676 · Cited by 720
Self-citationMosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood
Chang, Y. S., di Tomaso, E., McDonald, D. M., Jones, R., Jain, R. K., & Munn, L. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.26.14608 · Cited by 671
Lactate Is a Natural Suppressor of RLR Signaling by Targeting MAVS
Zhang, W., Wang, G., Xu, Z.-G., Tu, H., Hu, F., Dai, J., Chang, Y., Chen, Y., Lu, Y., Zeng, H., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.003 · Cited by 598
Schalper, K. A., Carleton, M., Zhou, M., Chen, T., Feng, Y., Huang, S.-P., Walsh, A. M., Baxi, V., Pandya, D., Baradet, T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0856-x · Cited by 548
Kaufmann, D. E., Kavanagh, D. G., Pereyra, F., Zaunders, J. J., Mackey, E. W., Miura, T., Palmer, S., Brockman, M., Rathod, A., Piechocka-Trocha, A., et al. (2007) · Nature Immunology · doi:10.1038/ni1515 · Cited by 524
Biomarker: Predictive or Prognostic?
Ballman, K. V. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.3651 · Cited by 522
Strioga, M., Pasukoniene, V., & Characiejus, D. (2011) · Immunology · doi:10.1111/j.1365-2567.2011.03470.x · Cited by 505
Bex, A., Mulders, P., Jewett, M., Wagstaff, J., van Thienen, J. V., Blank, C. U., van Velthoven, R., del Pilar Laguna, M., Wood, L., van Melick, H. H. E., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5543 · Cited by 492
Bratman, S. V., Yang, S. Y. C., Iafolla, M. A. J., Liu, Z., Hansen, A. R., Bedard, P. L., Lheureux, S., Spreafico, A., Razak, A. A., Shchegrova, S., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0096-5 · Cited by 487
Precursor exhausted T cells: key to successful immunotherapy?
Kallies, A., Zehn, D., & Utzschneider, D. T. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0223-7 · Cited by 465
Baseline C-Reactive Protein Is Associated With Incident Cancer and Survival in Patients With Cancer
Allin, K. H., Bojesen, S. E., & Nordestgaard, B. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8440 · Cited by 419
Lo Russo, G., Moro, M., Sommariva, M., Cancila, V., Boeri, M., Centonze, G., Ferro, S., Ganzinelli, M., Gasparini, P., Huber, V., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1390 · Cited by 408
p38 signaling inhibits mTORC1-independent autophagy in senescent human CD8+ T cells
Henson, S. M., Lanna, A., Riddell, N. E., Franzese, O., Macaulay, R., Griffiths, S. J., Puleston, D. J., Watson, A. S., Simon, A. K., Tooze, S. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75051 · Cited by 389
Voehringer, D., Koschella, M., & Pircher, H. (2002) · Blood · doi:10.1182/blood-2002-02-0657 · Cited by 352
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
Nabet, B. Y., Esfahani, M. S., Moding, E. J., Hamilton, E. G., Chabon, J. J., Rizvi, H., Steen, C. B., Chaudhuri, A. A., Liu, C. L., Hui, A. B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.001 · Cited by 347
Circulating Tumor Cell as a Diagnostic Marker in Primary Lung Cancer
Tanaka, F., Yoneda, K., Kondo, N., Hashimoto, M., Takuwa, T., Matsumoto, S., Okumura, Y., Rahman, S., Tsubota, N., Tsujimura, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1095 · Cited by 333
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
Lee, J. H., Long, G. V., Boyd, S., Lo, S., Menzies, A. M., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R. A., Mann, G. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx026 · Cited by 333
Lanna, A., Henson, S. M., Escors, D., & Akbar, A. N. (2014) · Nature Immunology · doi:10.1038/ni.2981 · Cited by 328
The role of C-reactive protein as a prognostic indicator in advanced cancer
Mahmoud, F. A., & Rivera, N. I. (2002) · Current Oncology Reports · doi:10.1007/s11912-002-0023-1 · Cited by 325
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Ribas, A., Lawrence, D., Atkinson, V., Agarwal, S., Miller, W. H., Carlino, M. S., Fisher, R., Long, G. V., Hodi, F. S., Tsoi, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0476-5 · Cited by 323
Immunotherapeutic approaches for small-cell lung cancer
Iams, W. T., Porter, J., & Horn, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0316-z · Cited by 311
Joseph, R. W., Elassaiss-Schaap, J., Kefford, R., Hwu, W.-J., Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, O., Robert, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2386 · Cited by 310
Self-citationParkinson, C. A., Gale, D., Piskorz, A. M., Biggs, H., Hodgkin, C., Addley, H., Freeman, S., Moyle, P., Sala, E., Sayal, K., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002198 · Cited by 297
Ding, J., Karp, J. E., & Emadi, A. (2017) · Cancer Biomarkers · doi:10.3233/cbm-160336 · Cited by 287
Senescence of T Lymphocytes: Implications for Enhancing Human Immunity
Akbar, A. N., Henson, S. M., & Lanna, A. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.09.002 · Cited by 285
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
Kim, C. G., Kim, K. H., Pyo, K.-H., Xin, C.-F., Hong, M. H., Ahn, B.-C., Kim, Y., Choi, S. J., Yoon, H. I., Lee, J. G., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz123 · Cited by 282
Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆
Spigel, D. R., Vicente, D., Ciuleanu, T. E., Gettinger, S., Peters, S., Horn, L., Audigier-Valette, C., Pardo Aranda, N., Juan-Vidal, O., Cheng, Y., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.01.071 · Cited by 270
Tumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis
Jeong, H., Kim, S., Hong, B.-J., Lee, C.-J., Kim, Y.-E., Bok, S., Oh, J.-M., Gwak, S.-H., Yoo, M. Y., Lee, M. S., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2545 · Cited by 268
Ferrucci, P. F., Gandini, S., Battaglia, A., Alfieri, S., Di Giacomo, A. M., Giannarelli, D., Cappellini, G. C. A., De Galitiis, F., Marchetti, P., Amato, G., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.180 · Cited by 262
Fehrenbacher, L., von Pawel, J., Park, K., Rittmeyer, A., Gandara, D. R., Ponce Aix, S., Han, J.-Y., Gadgeel, S. M., Hida, T., Cortinovis, D. L., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.039 · Cited by 260
Sanmamed, M. F., Carranza-Rua, O., Alfaro, C., Oñate, C., Martín-Algarra, S., Perez, G., Landazuri, S. F., Gonzalez, Á., Gross, S., Rodriguez, I., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3203 · Cited by 256
Laino, A. S., Woods, D., Vassallo, M., Qian, X., Tang, H., Wind-Rotolo, M., & Weber, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000842 · Cited by 249
Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer.
Brown, R. S., Leung, J. Y., Kison, P. V., Zasadny, K. R., Flint, A., & Wahl, R. L. (1999) · PubMed · Cited by 247
Guibert, N., Delaunay, M., Lusque, A., Boubekeur, N., Rouquette, I., Clermont, E., Mourlanette, J., Gouin, S., Dormoy, I., Favre, G., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.04.001 · Cited by 236
Bigot, F., Castanon, E., Baldini, C., Hollebecque, A., Carmona, A., Postel-Vinay, S., Angevin, E., Armand, J.-P., Ribrag, V., Aspeslagh, S., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.027 · Cited by 235
Self-citationPlunkett, F. J., Franzese, O., Finney, H. M., Fletcher, J. M., Belaramani, L. L., Salmon, M., Dokal, I., Webster, D., Lawson, A. D. G., & Akbar, A. N. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.12.7710 · Cited by 222
S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma
Harpio, R., & Einarsson, R. (2004) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2004.05.012 · Cited by 222
Metabolic Barriers to T Cell Function in Tumors
Sugiura, A., & Rathmell, J. C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701041 · Cited by 208
Lactate dehydrogenase: a marker of diminished antitumor immunity
Van Wilpe, S., Koornstra, R., Den Brok, M., De Groot, J. W., Blank, C., De Vries, J., Gerritsen, W., & Mehra, N. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1731942 · Cited by 208
Oxygen availability and metabolic reprogramming in cancer
Xie, H., & Simon, M. C. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.799973 · Cited by 206
Dal Bello, M. G., Filiberti, R. A., Alama, A., Orengo, A. M., Mussap, M., Coco, S., Vanni, I., Boccardo, S., Rijavec, E., Genova, C., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1828-0 · Cited by 195
Biological correlates of FDG uptake in non-small cell lung cancer
de Geus-Oei, L.-F., Krieken, J. H. J. M. V., Aliredjo, R. P., Krabbe, P. F. M., Frielink, C., Verhagen, A. F. T., Boerman, O. C., & Oyen, W. J. G. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2006.08.018 · Cited by 193
Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions
Cheng, M. L., Pectasides, E., Hanna, G. J., Parsons, H. A., Choudhury, A. D., & Oxnard, G. R. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21650 · Cited by 193
Mechanisms Underlying T Cell Immunosenescence: Aging and Cytomegalovirus Infection
Tu, W., & Rao, S. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02111 · Cited by 189
Increased expression of tumor necrosis factor-α is associated with advanced colorectal cancer stages
Al-Obeed, O. A., Alkhayal, K. A., Sheikh, A. A., Zubaidi, A. M., Vaali-Mohammed, M.-A., Boushey, R., Mckerrow, J. H., & Abdulla, M.-H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i48.18390 · Cited by 170
Valpione, S., Gremel, G., Mundra, P., Middlehurst, P., Galvani, E., Girotti, M. R., Lee, R. J., Garner, G., Dhomen, N., Lorigan, P. C., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.029 · Cited by 167
Ferrara, R., Mezquita, L., Auclin, E., Chaput, N., & Besse, B. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.003 · Cited by 163
Self-citationPires da Silva, I., Lo, S., Quek, C., Gonzalez, M., Carlino, M. S., Long, G. V., & Menzies, A. M. (2020) · Cancer · doi:10.1002/cncr.32522 · Cited by 163
Ferrara, R., Naigeon, M., Auclin, E., Duchemann, B., Cassard, L., Jouniaux, J.-M., Boselli, L., Grivel, J., Desnoyer, A., Mezquita, L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1420 · Cited by 163
Self-citationClinical Uses of Tumor Markers: A Critical Review
Duffy, M. J. (2001) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/20014091084218 · Cited by 161
Potential role of immunosenescence in cancer development
Fulop, T., Kotb, R., Fortin, C. F., Pawelec, G., de Angelis, F., & Larbi, A. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05370.x · Cited by 159
Tsukishiro, T., Donnenberg, A. D., & Whiteside, T. L. (2003) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-003-0395-6 · Cited by 158
Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy
Mercogliano, M. F., Bruni, S., Mauro, F. L., Elizalde, P. V., & Schillaci, R. (2021) · Cancers · doi:10.3390/cancers13030564 · Cited by 158
Cytomegalovirus Infection Reduces Telomere Length of the Circulating T Cell Pool
van de Berg, P. J. E. J., Griffiths, S. J., Yong, S.-L., Macaulay, R., Bemelman, F. J., Jackson, S., Henson, S. M., ten Berge, I. J. M., Akbar, A. N., & van Lier, R. A. W. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903442 · Cited by 157
Zhang, Z., Li, Y., Yan, X., Song, Q., Wang, G., Hu, Y., Jiao, S., & Wang, J. (2019) · Cancer Medicine · doi:10.1002/cam4.2024 · Cited by 156
Kordbacheh, T., Honeychurch, J., Blackhall, F. H., Finn, C. F., & Illidge, T. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx790 · Cited by 152
Agarwala, S. S., Keilholz, U., Gilles, E. M., Bedikian, A. Y., Wu, J., Kay, R., Stein, C. A., Itri, L. M., Suciu, S., & Eggermont, A. M. M. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.04.016 · Cited by 144
Seban, R., Nemer, J. S., Marabelle, A., Yeh, R., Deutsch, É., Ammari, S., Moya‐Plana, A., Mokrane, F., Gartrell, R. D., Finkel, G. G., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04411-7 · Cited by 143
Self-citationRole of antigen persistence and dose for CD4+T-cell exhaustion and recovery
Han, S., Asoyan, A., Rabenstein, H., Nakano, N., & Obst, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008437107 · Cited by 133
Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Gatter, K. C., Trarbach, T., Folprecht, G., Shi, M. M., Lebwohl, D., Jalava, T., Laurent, D., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2918 · Cited by 133
Sylman, J. L., Mitrugno, A., Atallah, M. B., Tormoen, G. W., Shatzel, J. J., Yunga, S. T., Wagner, T. H., Leppert, J. T., Mallick, P., & McCarty, O. J. T. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00078 · Cited by 129
Wagner, N. B., Forschner, A., Leiter, U., Garbe, C., & Eigentler, T. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0167-x · Cited by 129
Augustin, R. C., Delgoffe, G. M., & Najjar, Y. G. (2020) · Cancers · doi:10.3390/cancers12123802 · Cited by 129
Dummer, R., Lebbé, C., Atkinson, V. G., Mandalà, M., Nathan, P., Arance, A. M., Richtig, E., Yamazaki, N., Robert, C., Schadendorf, D., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1082-2 · Cited by 127
Self-citationIL-6 and TNF-α promote metastasis of lung cancer by inducing epithelial-mesenchymal transition
Shang, G.-S., Liu, L., & Qin, Y.-W. (2017) · Oncology Letters · doi:10.3892/ol.2017.6048 · Cited by 126
Seban, R., Mezquita, L., Berenbaum, A., Dercle, L., Botticella, A., Péchoux, C. L., Caramella, C., Deutsch, E., Grimaldi, S., Adam, J., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04615-x · Cited by 126
Self-citationPatients younger than 40 years with gastric carcinoma
Rugge, M., Busatto, G., Cassaro, M., Shiao, Y., Russo, V. M., Leandro, G., Avellini, C., Fabiano, A., Sidoni, A., & Covacci, A. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990615)85:12<2506::aid-cncr3>3.0.co;2-i · Cited by 125
Tumor Mutation Burden—From Hopes to Doubts
Addeo, A., Banna, G. L., & Weiss, G. J. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0626 · Cited by 123
Meermeier, E. W., Welsh, S. J., Sharik, M. E., Du, M. T., Garbitt, V. M., Riggs, D. L., Shi, C., Stein, C. K., Bergsagel, M., Chau, B. H., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0038 · Cited by 121
Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections
Philip, M., & Schietinger, A. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.04.014 · Cited by 120
Tamminga, M., de Wit, S., Hiltermann, T. J. N., Timens, W., Schuuring, E. M. D., Terstappen, L. W. M. M., & Groen, H. J. M. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0649-2 · Cited by 120
Seremet, T., Jansen, Y., Planken, S., Njimi, H., Delaunoy, M., El Housni, H., Awada, G., Schwarze, J. K., Keyaerts, M., Everaert, H., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2051-8 · Cited by 119
Kim, J. Y., Lee, K. H., Kang, J., Borcoman, É., Saâda-Bouzid, E., Kronbichler, A., Hong, S. H., Rezende, L. F. M., Ogino, S., Keum, N., et al. (2019) · Cancers · doi:10.3390/cancers11111699 · Cited by 112
Katsurada, M., Nagano, T., TACHIHARA, M. Y., Kiriu, T., Furukawa, K., KOYAMA, K., Otoshi, T., Sekiya, R., Hazama, D., Tamura, D., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13180 · Cited by 111
The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No
Prasad, V. K., & Addeo, A. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.001 · Cited by 105
Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment
Cassidy, M. R., Wolchok, R. E., Zheng, J., Panageas, K. S., Wolchok, J. D., Coit, D., Postow, M. A., & Ariyan, C. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.03.029 · Cited by 104
Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells
Zhang, Z., Lin, G., Yan, Y., Li, X., Hu, Y., Wang, J., Yin, B., Wu, Y., Li, Z., & Yang, X. (2018) · Oncogene · doi:10.1038/s41388-018-0221-4 · Cited by 102
Sorich, M. J., Rowland, A., Karapetis, C. S., & Hopkins, A. M. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.04.006 · Cited by 101
Iijima, Y., Hirotsu, Y., Amemiya, K., Ooka, Y., Mochizuki, H., Oyama, T., Nakagomi, T., Uchida, Y., Kobayashi, Y., Tsutsui, T., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.09.004 · Cited by 99
The Menin–Bach2 axis is critical for regulating CD4 T-cell senescence and cytokine homeostasis
Kuwahara, M., Suzuki, J., Tofukuji, S., Yamada, T., Kanoh, M., Matsumoto, A., Maruyama, S., Kometani, K., Kurosaki, T., Ohara, O., et al. (2014) · Nature Communications · doi:10.1038/ncomms4555 · Cited by 98
Ito, K., Schöder, H. M., Teng, R. S. Y., Humm, J. L., Ni, A., Wolchok, J. D., & Weber, W. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4211-0 · Cited by 98
The T cell differentiation landscape is shaped by tumour mutations in lung cancer
Ghorani, E., Reading, J. L., Henry, J. Y., Massy, M. R. D., Rosenthal, R., Turati, V., Joshi, K., Furness, A. J. S., Ben Aissa, A., Saini, S. K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0066-y · Cited by 96
Lee, J., Menzies, A. M., Carlino, M. S., McEvoy, A. C., Sandhu, S. K., Weppler, A. M., Diefenbach, R. J., Dawson, S., Kefford, R. F., Millward, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3926 · Cited by 93
Castello, A., Rossi, S., Mazziotti, E., Toschi, L., & Lopci, E. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.237768 · Cited by 90
Petrelli, F., Ardito, R., Merelli, B., Lonati, V., Cabiddu, M., Seghezzi, S., Barni, S., & Ghidini, A. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000520 · Cited by 90
Chardin, D., Paquet, M., Schiappa, R., Darcourt, J., Bailleux, C., Poudenx, M., Sciazza, A., Ilié, M., Benzaquen, J., Martin, N., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000645 · Cited by 90
Suzuki, J., Yamada, T., Inoue, K., Nabe, S., Kuwahara, M., Takemori, N., Takemori, A., Matsuda, S., Kanoh, M., Imai, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05854-6 · Cited by 88
Seban, R., Moya‐Plana, A., Antonios, L., Yeh, R., Marabelle, A., Deutsch, É., Schwartz, L. H., Gómez, R. G. H., Saenger, Y. M., Robert, C., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04757-3 · Cited by 88
Self-citationWong, A. N. M., Callahan, J., Keyaerts, M., Neyns, B., Mangana, J., Aberle, S., Herschtal, A., Fullerton, S., Milne, D., Iravani, A., et al. (2020) · Cancer Imaging · doi:10.1186/s40644-020-00313-2 · Cited by 78
Plunkett, F. J., Franzese, O., Belaramani, L. L., Fletcher, J. M., Gilmour, K. C., Sharifi, R., Khan, N., Hislop, A. D., Cara, A., Salmon, M., et al. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2005.03.006 · Cited by 74
Dercle, L., Ammari, S., Champiat, S., Massard, C., Ferté, C., Taihi, L., Seban, R., Aspeslagh, S., Mahjoubi, L., Kamsu-Kom, N., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.05.031 · Cited by 73
Self-citationThe Effect of Tumor Size on Necrosis and Polarographically Measured pO 2
Milross, C., Tucker, S. L., Mason, K. A., Hunter, N. R., Peters, L. J., & Las, L. M. (1997) · Acta Oncologica · doi:10.3109/02841869709109228 · Cited by 72
Dall’Olio, F. G., Gelsomino, F., Conci, N., Marcolin, L., Giglio, A. D., Grilli, G., Sperandi, F., Fontana, F., Terracciano, M., Fragomeno, B., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.03.005 · Cited by 72
Self-citationMarsavela, G., Lee, J., Calapre, L., Wong, S. Q., Pereira, M. R., McEvoy, A. C., Reid, A. L., Robinson, C., Warburton, L., Abed, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2251 · Cited by 65
Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma
Swan, D., Gurney, M. E., Krawczyk, J., Ryan, A. E., & O'Dwyer, M. E. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000350 · Cited by 64
Dall’Olio, F. G., Abbati, F., Facchinetti, F., Massucci, M., Melotti, B., Squadrilli, A., Buti, S., Formica, F., Tiseo, M., & Ardizzoni, A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920952994 · Cited by 59
Self-citationHashimoto, K., Kaira, K., Yamaguchi, O., Mouri, A., Shiono, A., Miura, Y., Murayama, Y., Kobayashi, K., Kagamu, H., & Kuji, I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030725 · Cited by 58
Alama, A., Coco, S., Genova, C., Rossi, G., Fontana, V., Tagliamento, M., Bello, M. G. D., Rosa, A., Boccardo, S., Rijavec, E., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071011 · Cited by 55
Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma
Braune, J., Keller, L., Schiller, F., Graf, E., Rafei-Shamsabadi, D. A., Wehrle, J., Follo, M., Philipp, U., Hussung, S., Pfeifer, D., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00174 · Cited by 55
Herbreteau, G., Langlais, A., Greillier, L., Audigier-Valette, C., Uwer, L., Hureaux, J., Moro‐Sibilot, D., Guisier, F., Carmier, D., Madelaine, J., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123861 · Cited by 53
Hopkins, A. M., Kichenadasse, G., McKinnon, R. A., Rowland, A., & Sorich, M. J. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.10.002 · Cited by 51
A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer
Guisier, F., Cousse, S., Jeanvoine, M., Thiberville, L., & Salaün, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-52913-z · Cited by 51
Dall'Olio, F., Calabrò, D., Conci, N., Argalia, G., Marchese, P., Fabbri, F., Fragomeno, B., Ricci, D., Fanti, S., Ambrosini, V., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.020 · Cited by 49
Self-citationChen, Q., Ge, F., Cui, W., Wang, F., Yang, Z., Guo, Y., Li, L., Bremner, R. M., & Lin, P. P. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.01.015 · Cited by 47
The Clinical Significance of PR, ER, NF-κB, and TNF-αin Breast Cancer
Zhou, X., Fan, W., Yang, G. F., & Yu, M. (2014) · Disease Markers · doi:10.1155/2014/494581 · Cited by 47
Papadaki, M. A., Sotiriou, A., Vasilopoulou, C., Filika, M., Aggouraki, D., Tsoulfas, P. G., Apostolopoulou, C. A., Rounis, K., Mavroudis, D., & Agelaki, S. (2020) · Cancers · doi:10.3390/cancers12061556 · Cited by 39
Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia
Wei, A. H., Ribera, J., Larson, R. A., Ritchie, D., Ghobadi, A., Chen, Y., Anderson, A., Santos, C. D., Franklin, J. L., & Kantarjian, H. M. (2021) · Leukemia · doi:10.1038/s41375-020-01089-x · Cited by 39
Onyema, O. O., Decoster, L., Njemini, R., Forti, L. N., Bautmans, I., De Waele, M., & Mets, T. (2015) · BMC Cancer · doi:10.1186/s12885-015-2013-3 · Cited by 38
Zhou, J., Dong, F., Cui, F., Xu, R., & Tang, X. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3269-x · Cited by 38
LDH-C4: a target with therapeutic potential for cancer and contraception
Gupta, G. S. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-012-1428-2 · Cited by 36
Zhang, W., Chen, C. Y., Zhou, Z.-H., Gao, S., Tee, T. J., Yang, L., Xu, Y., Pang, T., Xu, X., Sun, Q., et al. (2017) · Journal of Cancer · doi:10.7150/jca.19057 · Cited by 36
Knispel, S., Gassenmaier, M., Menzies, A. M., Loquai, C., Johnson, D. B., Franklin, C., Gutzmer, R., Hassel, J. C., Weishaupt, C., Eigentler, T., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.034 · Cited by 35
Gill, A. B., Rundo, L., Wan, J. C. M., Lau, D., Zawaideh, J. P., Woitek, R., Zaccagna, F., Beer, L., Gale, D. G., Sala, E., et al. (2020) · Cancers · doi:10.3390/cancers12123493 · Cited by 30
Seban, R., Assié, J., Giroux-Leprieur, É., Massiani, M., Soussan, M., Bonardel, G., Chouaid, C., Playe, M., Goldfarb, L., Duchemann, B., et al. (2020) · Annals of Nuclear Medicine · doi:10.1007/s12149-020-01539-7 · Cited by 29
Clinical Correlates of Response to Anti-PD-1–based Therapy in Patients With Metastatic Melanoma
Davis, E. J., Perez, M. C., Ayoubi, N., Zhao, S., Ye, F., Wang, D. Y., Sosman, J. A., Al-Rohil, R. N., Eroglu, Z., & Johnson, D. B. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000258 · Cited by 28
Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma
Inoue, H., Yokota, T., Hamauchi, S., Onozawa, Y., Kawakami, T., Shirasu, H., Notsu, A., Yasui, H., & Onitsuka, T. (2020) · Auris Nasus Larynx · doi:10.1016/j.anl.2020.01.003 · Cited by 26
Hakozaki, T., Hosomi, Y., Kitadai, R., Kitagawa, S., & Okuma, Y. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03271-1 · Cited by 26
Kiraga, Ł., Cheda, Ł., Taciak, B., Różańska, K., Tonecka, K., Szulc, A., Kilian, K., Górka, E., Rogulski, Z., Rygiel, T. P., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206706 · Cited by 24
Kang, B. J., Won, S., Lee, K., Lim, S., Son, S. H., Ahn, J. J., & Kim, B. C. (2020) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2019.0048 · Cited by 24
Valuation of Neutrophil/Lymphocyte Ratio in Renal Cell Carcinoma Grading and Progression
Arda, E., Yüksel, İ., Çakıroğlu, B., Akdenız, E., & Çilesiz, N. C. (2018) · Cureus · doi:10.7759/cureus.2051 · Cited by 23
Faehling, M., Kopp, M., Schwenk, B., Fallscheer, S., Kramberg, S., & Eckert, R. (2019) · Oncology · doi:10.1159/000500885 · Cited by 23
Deckers, E. A., Kruijff, S., Brouwers, A. H., van der Steen, K., Hoekstra, H. J., Thompson, J. F., García, D. V., & Wevers, K. P. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.07.011 · Cited by 19
Combination of Immunotherapy and Radiotherapy—The Next Magic Step in the Management of Lung Cancer?
Hendriks, L. E. L., Menis, J., Ruysscher, D. D., & Reck, M. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.106 · Cited by 15
Weppler, A. M., Pattison, A., Bhave, P., Ieso, P. B. D., Raleigh, J., Hatzimihalis, A., Gill, A. J., Balachander, S., Callahan, J., Chua, M. S.-T., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000700 · Cited by 14
Shi, P., Meng, X., NI, M., Sun, X., Xing, L., & Yu, J. (2015) · Oncology Letters · doi:10.3892/ol.2015.3673 · Cited by 13
ANALYSIS OF CD8+CD28−T-SUPPRESSOR CELLS IN GASTRIC CANCER PATIENTS
Shen, Y., Qu, Q., Zhu, Y., & Zhang, X. (2012) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2011.609575 · Cited by 11
Dogan, I., Karyağar, S., Karyağar, S. S., Kahraman, C., & Alver, A. (2014) · Annals of Nuclear Medicine · doi:10.1007/s12149-014-0877-y · Cited by 11
Additional lactate dehydrogenase (LDH) isoenzymes in normal testis and spermatozoa of adult man
Skude, G., von Eyben, F. E., & Kristiansen, P. (1984) · Molecular and General Genetics MGG · doi:10.1007/bf00328718 · Cited by 11
Popat, V., Lü, R., Ahmed, M., Park, J. Y., Xie, Y., & Gerber, D. E. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0814 · Cited by 10
Friedlander, P. A. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.01.74 · Cited by 8
LDH Isotyping for Checkpoint Inhibitor Response Prediction in Patients with Metastatic Melanoma
van Wilpe, S., Tolmeijer, S. H., de Vries, I. J. M., Koornstra, R. H. T., & Mehra, N. (2021) · Immuno · doi:10.3390/immuno1020005 · Cited by 4
Research works printed but not linked: 1
- Kinoshita, T., Ito, H. & Miki, C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 85, 2526–2531 (1999). · DOI
Cited by
The multiple roles of LDH in cancer
Claps, G., Faouzi, S., Quidville, V., Chehade, F., Shen, S., Vagner, S., & Robert, C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00686-2 · Cited by 351
Self-citationRadiotherapy, immunity, and immune checkpoint inhibitors
Lynch, C., Pitroda, S. P., & Weichselbaum, R. R. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00075-5 · Cited by 198
Small molecule inhibitors targeting the cancers
Liu, G., Chen, T., Zhang, X., Ma, X., & Shi, H. (2022) · MedComm · doi:10.1002/mco2.181 · Cited by 184
Zhang, L., Zhao, J., Hu, X., Wang, C., Jia, Y., Zhu, C., Xie, S., Lee, J., Li, F., & Ling, D. (2022) · Advanced Materials · doi:10.1002/adma.202206915 · Cited by 175
Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation
Ren, F., Fei, Q., Qiu, K. L., Zhang, Y., Zhang, H., & Sun, L. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03026-7 · Cited by 203
Metadata
- Authors
- Dall’Olio, F. G., Marabelle, A., Caramella, C., Garcia, C., Aldea, M., Chaput, N., Robert, C., & Besse, B.
- Affiliations
- Institut Gustave Roussy (FR)
- Inserm (FR)
- Hôpital Marie Lannelongue (FR)
- Université Paris-Saclay (FR)
- Corresponding author
- Besse, Benjamin
- ORCID
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2021-10-12
- Volume
- 19
- Issue
- 2
- Pages
- 75-90
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W3206266376
- Semantic Scholar
- c2bdf7b4eaa94713a47ba66f1cd342f1d860d7d0
- Cited by
- 350
- References
- 166
- Citations by year
- 2026: 48 · 2025: 97 · 2024: 98 · 2023: 63 · 2022: 44
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor burden, immune checkpoint inhibitors, FDG PET/CT, lactate dehydrogenase, circulating tumor DNA, circulating tumor cells, tumour biomarkers, treatment response prediction, tumor immunology, metastasis
- MeSH terms
- Immune Checkpoint Inhibitors, Humans, Neoplasms, Prognosis, Tumor Burden
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.